within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01E_SulfonamidesAndTrimethoprim.J01EB02_Sulfamethizole;

model Sulfamethizole
  extends Pharmacolibrary.Drugs.ATC.J.J01EB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01EB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sulfamethizole is a short-acting sulfonamide antibacterial agent, historically used for the treatment of urinary tract infections and other bacterial infections. It functions by inhibiting bacterial folic acid synthesis. Its clinical use has decreased significantly due to the availability of more effective and safer antibiotics, but it may still be used in certain regions or for specific indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers of both sexes; oral administration. (Primary source: J Antimicrob Chemother (1975) 1, 325-338 and Martindale: The Complete Drug Reference).</p><h4>References</h4><ol><li><p>Zayyad, H, et al., &amp; Paul, M (2017). Revival of old antibiotics: needs, the state of evidence and expectations. <i>International journal of antimicrobial agents</i> 49(5) 536–541. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2016.11.021\">10.1016/j.ijantimicag.2016.11.021</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28162982/\">https://pubmed.ncbi.nlm.nih.gov/28162982</a></p></li><li><p>Kerrn, MB, et al., &amp; Espersen, F (2003). Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model. <i>Antimicrobial agents and chemotherapy</i> 47(3) 1002–1009. DOI:<a href=\"https://doi.org/10.1128/AAC.47.3.1002-1009.2003\">10.1128/AAC.47.3.1002-1009.2003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12604534/\">https://pubmed.ncbi.nlm.nih.gov/12604534</a></p></li><li><p>Brittain, DC, et al., &amp; Neu, HC (1985). The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. <i>Journal of clinical pharmacology</i> 25(2) 82–88. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1985.tb02806.x\">10.1002/j.1552-4604.1985.tb02806.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3157705/\">https://pubmed.ncbi.nlm.nih.gov/3157705</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sulfamethizole;
